GENERIC GOLD CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 and 2018

(EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice to Reader

The accompanying unaudited condensed interim consolidated financial statements of Generic Gold Corp. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

		As at September 30, 2019	D	As at ecember 31, 2018
ASSETS				
Current assets	\$	-	\$	1,230
Cash Amounts receivable and other assets (note 5)	Ŧ	22,809	Ŧ	57,415
Total assets	\$	22,809	\$	58,645
LIABILITIES AND SHAREHOLDERS' DEFICIENCY				
Current liabilities Amounts payable and other liabilities (note 6)	\$	265,898	\$	82,993
Shareholders' de				
Share capital (note 7) Reserves (notes 8 and 9) Deficit		7,502,000 1,573,776 (9,318,865)		7,502,000 1,573,776 (9,100,124)
Total shareholders' deficiency		(243,089)		(24,348)
Total liabilities and shareholders' deficiency	\$	22,809	\$	58,645

Nature of operations and going concern (note 1) Contingencies (note 15)

Condensed Interim Consolidated Statement of Loss and Comprehensive Loss For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars)

(Unaudited)

		Three ths ended ember 30, 2019		Three ths ended ember 30, 2018		Nine ths ended ember 30, 2019		Nine hths ended tember 30, 2018
Operating expenses Exploration and evaluation expenditures (notes 4 and 11) General and administrative (notes 12 and 13) Reverse takeover transaction costs (note 3)	\$	- 88,112 -	\$	375,471 125,850 -	\$	8,250 210,491 -	\$	377,758 840,762 717,804
Net loss and comprehensive loss	\$	(88,112)	\$	(501,321)	\$	(218,741)	\$ (1,936,324)
Loss per share - basic and diluted	\$	(0.00)	\$	(0.01)	\$	(0.01)	\$	(0.05)
Weighted average number of common shares outstanding - basic and diluted (note 10)	3	37,953,388	37	7,171,214	3	37,953,388	(36,071,650

Condensed Interim Consolidated Statement of Cash Flows For the Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

Nine Months Ended September 30,	2019	2018
Operating activities		
Net loss for the period	\$ (218,74 ⁻	l) \$ (1,936,324)
Adjustments for:		
Share-based payments	-	477,300
Reverse takeover transaction costs	-	717,804
Non-cash working capital items:		
Amounts receivable and other assets	34,600	,
Amounts payable and other liabilities	182,90	5 84,844
Net cash flows from operating activities	(1,230) (607,238)
Investing activity Cash acquired from Amalgamation		5,841
		5,041
Net cash flows from investing activity	•	5,841
Financing activities		
Issue of common shares (note 7)		358,515
Share issuance cost		(4,386)
Net cash flows from financing activities		354, 129
		004, 120
Net change in cash	(1,230) (247,268)
Cash, beginning of period	1,230) 694,418
Cash, end of period	\$	\$ 447,150

Condensed Interim Consolidated Statement of Changes in Shareholders' Deficiency For the Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

	Shar	e ca	apital	-	Res		es are-based	ī		
	Number		Amount		Warrant reserve	р	ayments reserve		Deficit	Total
Balance, December 31, 2017	33,356,968		6,623,456		856,827		-		(6,791,301)	688,982
Issuance of common shares pursuant to Amalgamation (note 3) Issuance of units - flow-through Issuance of units	3,001,520 1,050,000 193,400		623,416 194,250 26,496		- 120,750 17,019		- - -		- - -	623,416 315,000 43,515
Issuance of units as commission (note 7(b)(ii)) Cost of issue - commission (note 7(b)(ii)) Cost of issue - warrants (note 7(b)(ii)) Cost of issue - cash	84,000 - - -		25,200 (34,860) (11,760) (4,386)		9,660 - 11,760 -		-			34,860 (34,860) - (4,386)
Share-based payments (note 9) Net loss for the period	-		-		-		477,300	_	(1,936,324)	 477,300 (1,936,324)
Balance, September 30, 2018	37,685,888	\$	7,441,812	\$	1,016,016	\$	477,300	\$	(8,727,625)	\$ 207,503
Shares issued pursuant to debt settlement Share-based payments (note 9) Net loss for the year	267,500 - -		60,188 - -		- -		- 80,460 -		- - (372,499)	60,188 80,460 (372,499)
Balance, December 31, 2018 Net loss for the period	37,953,388 -	\$	7,502,000	\$	1,016,016 -	\$	557,760 -	\$	(9,100,124) (218,741)	\$ (24,348) (218,741)
Balance, September 30, 2019	37,953,388	\$	7,502,000	\$	1,016,016	\$	557,760	\$	(9,318,865)	\$ (243,089)

The accompanying notes are an integral part of these unaudited condensed interim financial statements.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

1. Nature of operations and going concern

Generic Gold Corp. (the "Company" or "Generic Gold") was incorporated under the laws of the Province of Ontario on May 30, 2017 as Generic Gold Corporation ("Original Generic"). The Company's principal business activity is mineral exploration focused on high-grade gold opportunities in Yukon, Canada.

On February 20, 2018, Original Generic completed a transaction (the "Amalgamation") with Wamco Technology Group Ltd. ("Wamco"). The Amalgamation consisted of the acquisition by Wamco of all of the issued and outstanding securities in the capital of Original Generic by way of a three-cornered amalgamation, pursuant to which 2604935 Ontario Inc., a wholly-owned subsidiary of Wamco, amalgamated with Original Generic to form the Resulting Issuer, 1989670 Ontario Limited, a wholly-owned subsidiary of Wamco (note 3). On February 22, 2018, Wamco filed Articles of Amendment to change its name to "Generic Gold Corp.".

On February 28, 2018, Generic Gold received final approval to list its common shares on the Canadian Securities Exchange ("CSE"). Generic Gold began trading on the CSE on March 1, 2018 under the symbol "GGC". The head office of the Company is located at 141 Adelaide Street West, Suite 1660, Toronto, Ontario, M5H 3L5.

Generic Capital Corporation is the parent company of Generic Gold and owns approximately 72% of the Company's outstanding share capital as at September 30, 2019.

These unaudited condensed interim consolidated financial statements of the Company were reviewed, approved and authorized for issue by the Board of Directors on November 28, 2019.

These unaudited condensed interim consolidated financial statements have been prepared using accounting policies applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due.

The Company is at an exploration stage and as is common with many exploration companies, it raises financing to support its exploration and acquisition activities. The Company has incurred a current net loss of \$218,741 for the nine months ended September 30, 2019 and has an accumulated deficit of \$9,318,865 as at September 30, 2019. In addition, the Company had working capital deficiency of \$243,089 as at September 30, 2019.

However, existing funds may not be sufficient to explore potential exploration project acquisitions and in due course, further funding will be required. In the event that the Company is unable to secure further financing it may not be able to complete the development of its projects.

Although the Company has taken steps to verify title to the properties on which it is conducting exploration and in which it has an interest, in accordance with industry standards for the current stage of operations of such properties, these procedures do not guarantee the Company's title. Property title may be subject to government licensing requirements or regulations, unregistered prior agreements, social licensing requirements, unregistered claims, aboriginal claims, and non-compliance with regulatory and environmental requirements. The Company's assets may also be subject to increases in taxes and royalties, renegotiation of contracts and political uncertainty.

Due to limited working capital, the Company's ability to continue as a going concern is dependent on its ability to obtain additional sources of financing to successfully explore, evaluate and develop mineral projects, if they are proven successful, and ultimately, to achieve profitable operations. The success of these endeavours cannot be predicted at this time. These conditions indicate the existence of material uncertainties that cast significant doubt about the Company's ability to continue as a going concern. These financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

2. Significant accounting policies

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee. These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 - Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of November 28, 2019, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended December 31, 2018, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending December 31, 2019 could result in restatement of these unaudited condensed interim consolidated financial statements.

Changes in accounting policies

(i) IFRS 16, Lease

Effective January 1, 2019, the Company adopted IFRS 16 – Leases. The standard was issued by the IASB on January 13, 2016, and replaces IAS 17, "Leases". IFRS 16 brings most leases on-balance sheet for lessees under a single model, eliminating the distinction between operating and financing leases. Lessor accounting however remains largely unchanged and the distinction between operating and finance leases is retained. The adoption of this new standard did not have any impact on the Company's financial statements.

3. Amalgamation

On February 20, 2018, the Company completed an Amalgamation with Wamco. The Amalgamation consisted of the acquisition by Wamco of all of the issued and outstanding securities in the capital of Original Generic by way of a three-cornered amalgamation, pursuant to which 2604935 Ontario Inc., a wholly-owned subsidiary of Wamco, amalgamated with Original Generic to form the Resulting Issuer. The name of the Resulting Issuer is 1989670 Ontario Limited, a wholly-owned subsidiary of Wamco. As part of the Amalgamation, Wamco changed its name to "Generic Gold Corp.".

Pursuant to the Amalgamation, Original Generic shares and warrants were exchanged on a one-for-one basis for the issuance of Generic Gold shares and warrants.

As a result of the Amalgamation, the shareholders of Original Generic owned 91.7% of the outstanding shares of the amalgamated entity. The substance of the transaction is a reverse acquisition of a non-operating company. The transaction does not constitute a business combination, as Wamco does not meet the definition of a business under IFRS 3, Business Combinations. As a result, the transaction is accounted for as a capital transaction with Original Generic being identified as the acquirer and the equity consideration accounted for in accordance with IFRS 2, Sharebased Payment, measured at fair value.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

3. Amalgamation (continued)

The fair value of the consideration is as follows:

Fair value of 3,001,520 Generic Gold common shares	\$ 623,416
The consideration has been allocated as follows:	
Cash	\$ 5,841
Accounts payable and accrued liabilities	(100,229)
Reverse takeover transaction cost	717,804
	\$ 623,416

The value of the Generic Gold common shares was based on the share price of the June 27, July 20 and September 22, 2017 private placements of \$0.2077.

As Generic Gold has issued shares with a value in excess of the assets received, IFRS 2 would indicate that the difference is recognized in operations as a reverse takeover transaction cost. The amount of \$717,804 recognized as a reverse takeover transaction cost is the difference between the fair value of the consideration paid and the net identifiable liabilities of Wamco assumed by Generic Gold, and is charged to operating expenses.

4. Mineral properties

On May 30, 2017, the Company received a 100% interest in a number of mineral claims located in the Yukon Territory from Nevada Zinc Corporation ("Nevada Zinc"). As consideration the Company issued 25,000,000 common shares to Nevada Zinc at an estimated fair value of \$0.21 per share for aggregate share consideration of \$5,197,000. As this is considered a transaction with the sole shareholder of the Company, this value was recorded in equity.

The Company's property interests include the VIP Property (located in the Whitehorse Mining District), and other properties located in various regions of the Yukon Territory, Canada. The Company is continuing the evaluation of the precious metals potential of properties such as VIP, Livingstone and Goodman.

On May 1, 2013, Nevada Zinc entered into an amended option agreement ("Option Agreement") with Goldstrike Resources Ltd. ("Goldstrike") for the Summit Property which is located in the Yukon Territory. Under the amended agreement, Goldstrike has the option to earn a 100% interest in the Summit Property by meeting the following payments: (i) issue 200,000 shares by May 31, 2013 (issued); (ii) issue 300,000 shares and pay \$125,000 or issue shares in the equivalent amount, by October 31, 2015; (iii) issue 500,000 shares by October 31, 2016; and (iv) issue 600,000 shares and pay \$250,000 or issue shares in the equivalent amount, and incur \$1,000,000 in exploration expenditures by October 31, 2017. The Company would retain a 3.0% net smelter return ("NSR") and back-in option in which the Company could reacquire 30% of the property by paying Goldstrike \$2,500,000.

On April 30, 2016, Nevada Zinc agreed to extend all payment obligations by one year under the Option Agreement with Goldstrike for nil consideration.

On October 31, 2016, Nevada Zinc agreed to extend all payment obligations by an additional year under the Option Agreement with Goldstrike for nil consideration. Nevada Zinc reserved the right to shorten the extension period at any time by providing 30 day notice to Goldstrike.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

4. Mineral properties (continued)

Under the extended Option Agreement, Goldstrike has the option to earn a 100% interest in the Summit Property by meeting the following payments: (i) issue 200,000 shares by May 31, 2013 (issued); (ii) issue 300,000 shares and pay \$125,000 or issue shares in the equivalent amount, by October 31, 2017; (iii) issue 500,000 shares by October 31, 2018; and (iv) issue 600,000 shares and pay \$250,000 or issue shares in the equivalent amount, and incur \$1,000,000 in exploration expenditures by October 31, 2019. The Company would retain a 3.0% NSR and back-in option in which the Company could reacquire 30% of the property by paying Goldstrike \$2,500,000.

On April 10, 2018, Goldstrike abandoned and surrendered the Option Agreement in respect of all mineral claims of the Summit Property and the claims reverted to the Company.

5. Amounts receivable and other assets

	Se	As at eptember 30, 2019	D	As at ecember 31, 2018
Sales tax receivable - (Canada) Prepaid expenses	\$	22,660 149	\$	52,995 4,420
	\$	22,809	\$	57,415

6. Amounts payable and other liabilities

Amounts payable and other liabilities of the Company are principally comprised of amounts outstanding for purchases relating to exploration and acquisition costs and general operating activities.

	As at September 30, 2019	[As at December 31, 2018
Trade payables Accrued liabilities	\$ 241,148 24,750	\$	60,438 22,555
	\$ 265,898	\$	82,993

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

7. Share capital

a) Authorized share capital

The authorized share capital consists of an unlimited number of common shares. The common shares do not have a par value. All issued shares are fully paid.

b) Common shares issued

(i) On June 27, July 20 and September 22, 2017, the Company completed the first, second and third tranches, respectively, of a private placement financing of 7,542,131 units at a price of \$0.30 per unit and 240,000 flow-through units at price of \$0.40 per flow-through unit for a gross proceeds of \$2,358,639. Each unit consists of one common share of the Company and one common share purchase warrant. Each flow-through unit consists of one flow-through common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share of the Company at a price of \$0.50 per common share for a period of 36 months following the closing date. Upon 30 days' written notice to the holders of the warrants, the Company may accelerate the expiration date of the warrants if after the common shares have been listed on a recognized Canadian stock exchange, the closing price of the common shares exceeds \$1.00 for twenty (20) consecutive trading days.

In connection with the private placement, a finder's fee was paid to certain eligible finders in an amount equal to 8% of proceeds raised. The finder's fee was comprised of a cash payment of \$15,520 and issuance of 574,837 commission units of the Company, at a fair value of \$0.30 per commission unit. Each commission unit consists of one common share of the Company and one warrant.

The fair value of the 8,356,968 warrants was estimated at \$771,420 using the Black-Scholes option pricing model. The following weighted average assumptions were used: risk-free interest rate - 1.04%; expected volatility - 100% which is based on the historical volatility of a comparable company, Nevada Zinc; expected dividend yield - nil; and expected life - 36 months.

In addition, an aggregate of 620,171 broker warrants were issued representing an amount equal to 8% of the number of common shares placed by eligible finders pursuant to the private placement. Each broker warrant entitles the holder to acquire one unit of the Company at an exercise price of \$0.30 per unit commencing on the date of listing of the common shares of the Company on a recognized Canadian stock exchange and ending 24 months after the date of listing. The fair value of the 620,171 broker warrants was estimated at \$85,407 using the Black-Scholes option pricing model. The following weighted average assumptions were used: risk-free interest rate - 0.96%; expected volatility - 85% which is based on the historical volatility of a comparable company, Nevada Zinc; expected dividend yield - nil; and expected life - 24 months.

(ii)On July 23 and September 21, 2018, the Company completed the first and second tranches of a private placement financing of 1,050,000 flow-through units at a price of \$0.30 per flow-through unit and 193,400 units at price of \$0.225 per unit for a gross proceeds of \$358,515. Each flow-through unit consists of one flow-through common share of the Company and one common share purchase warrant. Each unit consists of one common share of the Company and one common share purchase warrant entitles the holder to acquire one common share of the Company at a price of \$0.50 per common share for a period of 36 months following the closing date.

In connection with the private placement, a finder's fee was paid to certain eligible finders in an amount equal to 8% of proceeds raised. The finder's fee was comprised of the issuance of 84,000 commission units of the Company, at a fair value of \$0.30 per commission unit. Each commission unit consists of one common share of the Company and one warrant.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

7. Share capital (continued)

The fair value of the 1,327,400 warrants was estimated at \$147,429 using the Black-Scholes option pricing model. The following weighted average assumptions were used: risk-free interest rate - ranging from 2.03% to 2.21%; expected volatility - 100% which is based on the historical volatility of a comparable company, Nevada Zinc; expected dividend yield - nil; and expected life - 36 months.

In addition, an aggregate of 84,000 broker warrants were issued representing an amount equal to 8% of the number of common shares placed by eligible finders pursuant to the private placement. Each broker warrant entitles the holder to acquire one unit of the Company at an exercise price of \$0.30 per unit for a period of 36 months from the date of issuance. The fair value of the 84,000 broker warrants was estimated at \$11,760 using the Black-Scholes option pricing model. The following weighted average assumptions were used: risk-free interest rate - 2.03%; expected volatility - 100% which is based on the historical volatility of a comparable company, Nevada Zinc; expected dividend yield - nil; and expected life - 36 months.

(iii) On October 17, 2018, the Company entered into a debt settlement agreement with an arm's length creditor pursuant to which the Company has agreed to settle an aggregate of \$60,188 of indebtedness through the issuance of an aggregate of 267,500 common shares of the Company at a price of \$0.225 per common share. The common shares issued pursuant to the debt settlement will be subject to a four month and one day hold period pursuant to applicable securities laws.

8. Warrants

The following table reflects the continuity of warrants for the period ended September 30, 2019:

	Number of warrants	Weighted exercise	
Balance, May 30, 2017	-		-
Issued (note 7(b)(i))	8,97	7,139	0.49
Balance, December 31, 2017	•	7 7,139	0.49
Issued (note 7(b)(ii))		11,400	0.49
Balance, September 30, 2019 and December 31, 2018	10,38	38,539	0.49

The following table reflects the actual warrants issued and outstanding as of June 30, 2019:

Issue date	Number of warrants outstanding	Grant date fair value (\$)	Exercise price (\$)	Expiry date
June 27, 2017	176,400	24,167	0.30	March 1, 2020 ⁽¹⁾
July 20, 2017	155,507	21,460	0.30	March 1, 2020 ⁽¹⁾
September 22, 2017	288,264	39,780	0.30	March 1, 2020 ⁽¹⁾
June 27, 2017	3,096,300	285,815	0.50	June 27, 2020
July 20, 2017	2,817,473	260,077	0.50	July 20, 2020
September 22, 2017	2,443,195	225,528	0.50	September 22, 2020
July 23, 2018	1,134,000	130,410	0.50	July 23, 2021
July 23, 2018	84,000	11,760	0.30	July 23, 2021
September 18, 2018	193,400	17,019	0.50	September 21, 2021
	10,388,539	1,016,016	0.49	

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

8. Warrants (continued)

⁽¹⁾ Each broker warrant entitles the holder to acquire one Unit of the Company at an exercise price of \$0.30 per Unit commencing March 1, 2018, the date of listing of the common shares of the Company on a recognized Canadian stock exchange, and ending 24 months after the date of listing.

9. Stock options

The following table reflects the continuity of stock options for the period ended September 30, 2019:

	Number of stock options	ted average ise price (\$)
Balance, December 31, 2018 Expired	3,765,000 (1,180,000)	\$ 0.29 0.29
Balance, September 30, 2019	2,585,000	\$ 0.29

(i) On February 20, 2018, the Company granted a total of 3,225,000 stock options to certain directors, officers and consultants of the Company. The stock options are exercisable at a price of \$0.30 per share, expire on February 20, 2023 and vested immediately. The fair value of the stock options was estimated to be \$477,300 using the Black-Scholes option pricing model on the following assumptions: exercise price of \$0.30, risk free interest rate of 2.12%, an expected life of 5 years and an expected volatility of 100%. During the year ended December 31, 2018, share based compensation of \$477,300, were recorded in the consolidated statements of loss and comprehensive loss.

(ii) On October 17, 2018, the Company granted a total of 540,000 stock options to certain directors, officers and consultants of the Company. The stock options are exercisable at a price of \$0.25 per share, expire on October 17, 2021 and vested immediately. The fair value of the stock options was estimated to be \$80,460 using the Black-Scholes option pricing model on the following assumptions: exercise price of \$0.25, risk free interest rate of 2.32%, an expected life of 3 years and an expected volatility of 100%. During the year ended December 31, 2018, share based compensation of \$80,460, were recorded in the consolidated statements of loss and comprehensive loss.

The following table reflects the Company's stock options outstanding and exercisable as at September 30, 2019:

Options outstanding and exercisable	Grant date fair value (\$)	Exercise price (\$)	remaining contractual life (years)	Expiry date
2,225,000 360,000	329,300 53,640	0.30 0.25	3.39 2.05	February 20, 2023 October 17, 2021
2,585,000	382,940	0.29	3.20	

10. Net loss per common share

The calculation of basic loss per share for the nine months ended September 30, 2019 was based on the loss attributable to common shareholders of 218,741 (2018 – 1,936,324) and the weighted average number of common shares outstanding of 37,953,388 (2018 – 35,512,756). Diluted loss per share for the nine months ended September 30, 2019 did not include the effect of 10,388,539 (2018 – 10,388,539) and 2,585,000 (2018 – 3,225,000) warrants and options, respectively as they are anti-dilutive.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

11. Exploration and evaluation expenditures

Nine months ended September 30,	20	019	20	18
Yukon, Canada				
Geological consulting	\$	-	\$	24,717
Camp construction		-		2,178
Geophysics		-		10,000
Exploratory (recovery)		-		(40,000)
Laboratory and analysis		8,250		2,268
Miscellaneous		-		3,124
Exploration and evaluation expenditures	\$	8,250	\$	2,287
12. General and administrative expenses	· ·			· · · ·
12. General and administrative expenses		2019		2018
12. General and administrative expenses Nine months ended September 30,		2019		2018
12. General and administrative expenses Nine months ended September 30, Salaries and benefits	\$	2019 93,953	\$	2018 151,540
12. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees		2019 93,953 56,748		2018 151,540 70,633
 12. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees Office and administrative expenses 		2019 93,953 56,748 6,076		2018 151,540 70,633 33,534
12. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees Office and administrative expenses Accounting fees		2019 93,953 56,748 6,076 33,584		2018 151,540 70,633 33,534 20,055
12. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees Office and administrative expenses Accounting fees Transfer agent fees		2019 93,953 56,748 6,076		2018 151,540 70,633 33,534 20,055 34,456
12. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees Office and administrative expenses Accounting fees Transfer agent fees Share-based payments		2019 93,953 56,748 6,076 33,584 9,924		2018 151,540 70,633 33,534 20,055 34,456 477,300
I2. General and administrative expenses Nine months ended September 30, Salaries and benefits Professional fees Office and administrative expenses Accounting fees Transfer agent fees		2019 93,953 56,748 6,076 33,584 9,924 - 10,206		2018 151,540 70,633 33,534 20,055 34,456 477,300 53,244

13. Related party transactions and major shareholders

Related party transactions

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

The below noted transactions are in the normal course of business and are measured at the exchange amount, as agreed to by the parties, and approved by the Board of Directors.

Remuneration of key management personnel of the Company was as follows:

Nine months ended September 30,

	2019	2018
Salaries ⁽¹⁾ Share-based payments	\$ 90,000 -	\$ 144,000 451,400
	\$ 90,000	\$ 547,400

⁽¹⁾ Salaries paid for the services of the Chief Executive Officer and Chief Financial Officer included in general and administrative expenses on the statement of loss and comprehensive loss.

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

13. Related party transactions and major shareholders (continued)

Major shareholders

To the knowledge of the directors and senior officers of the Company as at September 30, 2019, no person or corporation beneficially owns or exercises control or direction over common shares of the Company carrying more than 10% of the voting rights attached to all common shares of the Company other than as set out below:

Major shareholder	Number of common shares	Percentage of outstanding common shares
Generic Capital Corporation	26,646,033	71.64 %

14. Segmented information

The Company's operations comprise a single reporting operating segment engaged in mineral exploration in Canada. As the operations comprise a single reporting segment, amounts disclosed in the statement of loss and comprehensive loss for the period also represent segmented amounts. All of the Company's operations, assets and liabilities are in Canada.

15. Contingencies

The Company's exploration activities are subject to government laws and regulations, including tax laws and laws and regulations governing the protection of the environment. The Company believes that its operations comply in all material respects with all applicable past and present laws and regulations. The Company records provisions for any identified obligations, based on management's estimate at the time. Such estimates are, however, subject to changes in laws and regulations.

16. Proposed Transactions

On September 17, 2019, DNA Genetics Inc. ("DNA"), a globally recognized leading cannabis brand, and Generic Gold announced that they have entered into a definitive agreement (the "Definitive Agreement") to complete their previously announced business combination (the "Proposed Transaction"). Upon completion of the Proposed Transaction, the securityholders of DNA will hold substantially all of the outstanding securities of Generic Gold (the "Resulting Issuer"), and the Resulting Issuer will carry on the business of DNA.

Pursuant to the Definitive Agreement entered into among DNA, Generic Gold and 1222150 B.C. Ltd., a wholly-owned subsidiary of Generic Gold ("Subco"), and upon the satisfaction or waiver of the conditions set out therein, the following, among other things, will be completed in connection with the consummation of the Proposed Transaction:

Generic Gold will continue from the Province of Ontario into the Province of British Columbia (the "Continuance") and will: (i) effect a capital restructuring (the "Restructuring") to (A) create a class of restricted voting shares having the same economic power (on an as-converted basis) as the issued and outstanding common shares ("Generic Gold Shares"), and (B) consolidate the Generic Gold Shares such that the aggregate number of Common Shares outstanding post-consolidation be no greater than 1,000,000 (the "Generic Share Consolidation"); (ii) approve the adoption of Articles under the Business Corporations Act (British Columbia) which will effect the Restructuring (the "Share Structure Amendment"); (iii) change its name to "OG DNA Holdings Inc." or such other name as determined by DNA (the "Name Change"); (iv) appoint MNP LLP as auditors of Resulting Issuer; and (v) approve a new equity compensation plan (collectively, all of the foregoing are referred to as the "Shareholder Approval Matters").

Notes to Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2019 and 2018 (Expressed in Canadian Dollars) (Unaudited)

16. Proposed Transactions (continued)

- Subco will merge with and into the DNA, pursuant to which, among other things, all outstanding common shares of DNA (the "DNA Shares") and all securities convertible into DNA Shares shall be exchanged for replacement securities of the Resulting Issuer, one-for-one on a post-consolidation basis, exercisable in accordance with their terms; and
- the board of directors and management of the Resulting Issuer will be replaced with nominees of DNA.

The Proposed Transaction is subject to the conditions set out in the Definitive Agreement, including but not limited to obtaining the requisite approval of DNA's and Generic Gold's securityholders, completion of a brokered private placement in such amount as is necessary to satisfy the minimum listing requirements of the Canadian Securities Exchange ("CSE"), and completion by Generic Gold of the Continuance, the Generic Share Consolidation, the Name Change, and the Share Structure Amendment.

Trading in the Generic Gold Shares was halted by the Canadian Securities Exchange on March 25, 2019. Pending completion of the Proposed Transaction, which is anticipated to occur in Q4 2019, it is expected that the Generic Gold Shares will remain halted for trading.

Following the closing of the Proposed Transaction, it is anticipated that the Resulting Issuer will be led by Charles Phillips, Chief Executive Officer, Don Morris, Chief Cannabis Officer and Aaron Yarkoni, Chief Research Officer. The Resulting Issuer's board of directors (the "Board") is expected to be comprised of seven representatives, all of whom will be nominated by DNA.

The Proposed Transaction is conditional upon the Resulting Issuer's common shares being listed on the CSE. Listing will be subject to satisfying the CSE's listing requirements.